Asia Pacific Peripheral Vascular Devices Market Report

To learn more about this report, Download Free Sample Report

Asia Pacific Peripheral Vascular Devices Market Size

The Asia Pacific peripheral vascular devices market size was valued at USD 1098.81 million in 2025 and is anticipated to reach USD 1192.54 million in 2026 from USD 2295.47 million by 2034, growing at a CAGR of 8.53% during the forecast period from 2026 to 2034.

The Asia Pacific peripheral vascular devices market encompasses a specialized array of medical instruments including stents, balloons, catheters, and atherectomy systems designed to diagnose and treat diseases affecting blood vessels outside the heart and brain. According to the World Health Organization, noncommunicable diseases including cardiovascular diseases, diabetes, cancer, and chronic respiratory diseases accounted for 86% of all deaths in the Western Pacific Region in 2019, creating a substantial clinical burden that necessitates minimally invasive interventions. This market is distinct due to its rapid adoption of endovascular technologies in emerging economies where open surgical options are often less accessible. As per the International Diabetes Federation, an estimated 1 in 11 adults in the South East Asia region lived with diabetes in 2021, and the number is projected to rise to 152 million by 2045, significantly increasing the population at risk for vascular complications. These epidemiological realities anchor the regional demand for high-precision delivery systems and durable implants. The industry is increasingly shifting toward drug-coated technologies, which reduce restenosis rates and improve long-term patency. According to the Journal of Vascular Surgery, newer endovascular technologies can reduce radiation exposure during peripheral interventions while supporting image-guided treatment, reflecting the continuing shift toward minimally invasive vascular care. This technological evolution ensures that the Asia Pacific peripheral vascular devices market remains dynamic and responsive to the rising prevalence of metabolic disorders while maintaining a focus on improving limb salvage rates and patient quality of life.

MARKET DRIVERS

Rising Prevalence of Diabetes and Metabolic Disorders

The escalating global incidence of diabetes mellitus is a key factor propelling the Asia Pacific peripheral vascular devices market expansion by accelerating the onset of peripheral artery disease and critical limb ischemia. According to the International Diabetes Federation, an estimated 1 in 11 adults in the South East Asia region lived with diabetes in 2021, and the number of people with diabetes is projected to rise to 152 million by 2045, creating a vast population at risk for vascular complications. Diabetic patients are more likely to develop peripheral artery disease due to accelerated atherosclerosis and vascular complications. This statistical correlation directly translates into increased demand for angioplasty balloons and stents required to restore blood flow and prevent amputation. Furthermore, chronic kidney disease, which is common among diabetic populations, exacerbates vascular calcification, making standard interventions more complex and requiring specialized devices such as lithotripsy systems. As per the World Health Organization, chronic kidney disease is an increasing global health burden, and diabetes and hypertension are among its leading causes, creating additional demand for vascular access and intervention. These comorbidities create a recurring need for device-assisted therapies rather than one-time fixes. Consequently, the Asia Pacific peripheral vascular devices market benefits from a structural driver where metabolic disorders sustain high procedural volumes and drive innovation in devices capable of treating heavily calcified lesions.

Aging Population and Increased Life Expectancy

The demographic shift toward an older population further contributes to the Asia Pacific peripheral vascular devices market growth by expanding the cohort susceptible to age-related vascular degeneration and arterial stiffness. According to the United Nations Economic and Social Commission for Asia and the Pacific, the population aged 60 years and older in Asia and the Pacific is projected to approach 1.5 billion by 2050, leading to a higher prevalence of age-related vascular conditions. Aging is a primary risk factor for peripheral artery disease as arterial walls lose elasticity and plaque accumulation increases over time. The statistical growth in the elderly population ensures a steady pipeline of patients requiring diagnostic angiography and therapeutic interventions. Additionally, increased life expectancy means that patients are more likely to seek treatment for mobility-limiting claudication to maintain an active lifestyle rather than accepting disability. As per population-based research published in the Journal of the American College of Cardiology, vascular disease prevalence increases substantially with advancing age, with more than 20% of people in their eighties having vascular disease in at least one arterial territory. This demographic reality drives demand for both emergency limb-saving procedures and elective interventions for quality-of-life improvement. Thus, the Asia Pacific peripheral vascular devices market is propelled by demographic inevitabilities where longevity creates sustained demand for vascular care solutions.

MARKET RESTRAINTS

High Out-of-Pocket Healthcare Expenditure

The substantial financial burden associated with advanced vascular procedures is hampering the Asia Pacific peripheral vascular devices market expansion by limiting access for a large portion of the population in emerging economies. According to the World Bank, out-of-pocket spending represented 43.89% of current health expenditure in India, 31.08% in Indonesia, and 39.20% in Viet Nam in 2023, demonstrating persistent household exposure to healthcare costs across major Asian markets. This economic barrier forces individuals to delay necessary treatments or opt for cheaper, less effective alternatives, leading to worsened clinical outcomes and reduced device utilization. The statistical disparity in affordability is evident across the region as household direct payments remain a significant component of healthcare financing. Additionally, insurance coverage for elective peripheral vascular procedures such as stenting for claudication is often limited or excluded in basic health plans. These financial constraints restrict the adoption of premium devices like drug-eluting stents and force providers to rely on lower-cost generic implants that may offer inferior longevity. Consequently, the Asia Pacific peripheral vascular devices market faces a persistent headwind where economic barriers limit market penetration and slow the adoption of next-generation technologies in price-sensitive healthcare systems.

Shortage of Skilled Interventional Specialists

The limited number of physicians specifically trained in complex peripheral vascular interventions further constrains the Asia Pacific peripheral vascular devices market by restricting the volume of advanced procedures that can be performed effectively. According to the World Health Organization, health workforce shortages remain a major challenge across the Western Pacific Region, particularly in countries with limited specialist capacity and uneven distribution of healthcare professionals. This scarcity means that many general practitioners perform foot and ankle procedures with varying levels of proficiency, which can lead to inconsistent outcomes and higher complication rates. The statistical gap in specialized training limits the adoption of advanced devices that require precise technical skills for optimal placement, such as directional atherectomy systems or complex stent grafts. As per the World Health Organization, countries across the Western Pacific Region continue to strengthen specialist capacity and health workforce distribution to address gaps in access to quality care. Furthermore, the learning curve for new technologies such as robotic-assisted surgery is steep, requiring significant time and resource investment from hospitals. These human capital constraints hinder the widespread implementation of innovative devices. Thus, the Asia Pacific peripheral vascular devices market must navigate a talent shortage that limits procedural capacity and slows the diffusion of advanced surgical technologies.

MARKET OPPORTUNITIES

Expansion into Below-the-Knee Interventions

The growing focus on treating infrapopliteal or below-the-knee arterial disease is a notable opportunity for the Asia Pacific peripheral vascular devices market by addressing a previously underserved clinical segment with high amputation risks. According to the 2024 ACC/AHA guideline for lower extremity peripheral artery disease, revascularization decisions should be based on disease severity and clinical presentation, while infrapopliteal interventions require careful patient selection because evidence remains limited for some indications. Recent advancements in micro-catheters and low-profile balloons now enable safer navigation of these small-diameter vessels, opening new therapeutic avenues. The statistical potential is substantial because peripheral artery disease and chronic limb-threatening ischemia affect large numbers of patients worldwide and are particularly associated with diabetes. Manufacturers are developing specialized drug-coated balloons and other technologies tailored for these delicate anatomies, which command premium pricing. As per the Journal of Endovascular Therapy, clinical research continues to evaluate endovascular strategies for below-the-knee disease and their effects on vessel patency and wound healing. This niche expansion allows companies to differentiate their portfolios and capture high-value market share. Consequently, the Asia Pacific peripheral vascular devices market can leverage this clinical unmet need to drive innovation and revenue growth in a segment with limited competition.

Integration of Robotics and Artificial Intelligence

The incorporation of robotic assistance and artificial intelligence into peripheral vascular procedures offers a substantial opportunity for the Asia Pacific peripheral vascular devices market by enhancing precision and reducing radiation exposure. According to a study published in the Journal of the American College of Cardiology, robotic-assisted peripheral vascular intervention reduced primary operator radiation exposure by approximately 96.9% compared with table-side dosimetry during femoropopliteal interventions. This technological advantage appeals to interventionalists seeking to improve ergonomics and procedural accuracy in lengthy cases. The statistical improvement in radiation protection encourages hospitals in developed markets like Japan and South Korea to consider robotic platforms, which require compatible disposable devices such as specialized catheters and guidewires. As per a 2026 randomized study published in BMJ, robotic-assisted angiography achieved 100% clinical success and 100% technical success while significantly reducing primary operator radiation exposure compared with manual angiography. Manufacturers who integrate smart sensors into their devices can capture valuable data that further refines these algorithms, creating a sticky ecosystem. This convergence of hardware and software creates new revenue streams beyond traditional device sales. Thus, the Asia Pacific peripheral vascular devices market can capitalize on the digital transformation of the cath lab by offering integrated solutions that enhance clinical performance and operational efficiency.

MARKET CHALLENGES

Risk of Restenosis and Thrombosis

The inherent risk of vessel renarrowing (restenosis) and blood clot formation (thrombosis) is a significant challenge to the Asia Pacific peripheral vascular devices market by necessitating repeat interventions and complicating patient management. According to the Society for Vascular Surgery, longer femoropopliteal lesions are associated with increased restenosis and reintervention concerns, and current guidelines recommend drug-coated balloons, drug-eluting stents, or bare metal stents for lesions longer than 5 cm to reduce restenosis and reintervention. This clinical limitation erodes confidence in certain device classes and drives payers to demand evidence of long-term durability before covering new technologies. The statistical prevalence of adverse events leads to stringent post-market surveillance requirements and potential recalls, which damage brand reputation. As per the American College of Cardiology, diabetes and peripheral artery disease together substantially increase the risk of major adverse cardiovascular and limb events, making long-term device performance particularly important in high-risk populations. These clinical realities force manufacturers to continuously refine materials and coatings to improve patency, but at the cost of slower adoption rates. Consequently, the Asia Pacific peripheral vascular devices market faces ongoing scrutiny where clinical performance metrics directly influence purchasing decisions, requiring constant innovation to overcome biological limitations.

Regulatory Fragmentation and Approval Delays

The lack of harmonized regulatory frameworks across Asia Pacific countries further challenges the Asia Pacific peripheral vascular devices market expansion by creating complex and time-consuming approval processes for new products. According to the International Medical Device Regulators Forum, medical device regulatory systems increasingly emphasize harmonization and reliance on common principles to reduce unnecessary duplication and improve access to safe medical technologies. This statistical variability increases compliance costs and discourages smaller manufacturers from entering multiple markets simultaneously. The absence of a unified regional regulatory body similar to the European Medicines Agency means that companies must navigate a patchwork of rules, which slows down the availability of innovative devices. As per the International Medical Device Regulators Forum, the use of common regulatory principles and work-sharing mechanisms can reduce regulatory duplication and improve efficiency. These administrative hurdles limit patient access to the latest technologies and reduce the competitiveness of the regional market. Consequently, the Asia Pacific peripheral vascular devices market faces ongoing operational inefficiencies where regulatory fragmentation impedes timely product introduction and market expansion.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Type Insights

The stents segment occupied the largest share of the Asia-pacific market in 2025. The dominance of stents segment in this regional market can be credited to their critical role in maintaining vessel patency following angioplasty and treating complex atherosclerotic lesions. The dominance of stents is driven by the high incidence of femoropopliteal artery disease, which affects the superficial femoral artery and popliteal artery, requiring robust mechanical support to prevent recoil. According to the Society for Vascular Surgery, current guidelines recommend drug-coated balloons, drug-eluting stents, or bare metal stents for femoropopliteal lesions longer than 5 cm because these approaches can reduce restenosis and reintervention compared with plain balloon angioplasty. This anatomical prevalence creates a consistent and high-volume demand for both drug-eluting and bare metal stents. The statistical correlation between lesion length and stent usage means that longer diseased segments require more advanced treatment strategies and can increase procedural complexity. Furthermore, clinical guidelines increasingly recommend primary stenting for certain lesion types to improve primary patency rates compared to angioplasty alone. As per the Journal of Endovascular Therapy, randomized clinical evidence supports the use of modern endovascular technologies for improving patency in complex femoropopliteal disease. These clinical outcomes reinforce the preference for stenting in complex cases. According to publicly available 2025 market data, peripheral stents represented 22.2% of global peripheral vascular device revenue in 2025. Consequently, the Asia Pacific peripheral vascular devices market relies on stents as its primary revenue generator driven by the structural need to maintain blood flow in high-stress arterial segments subject to bending and compression.

On the other hand, the chronic total occlusion (CTO) devices segment is predicted to register a promising CAGR of 10.5% over the forecast period owing to the complexity of treating completely blocked arteries, the shift toward limb salvage and the rising prevalence of critical limb ischemia, where complete arterial occlusion threatens limb viability and necessitates specialized recanalization tools. According to the American College of Cardiology and American Heart Association, diabetes is associated with an increased risk of peripheral artery disease with an odds ratio ranging from 1.89 to 4.05, reinforcing the clinical need for advanced revascularization strategies in high-risk patients. This severe clinical condition drives demand for dedicated CTO devices, such as reentry catheters, crossing wires, and micro-dissection tools designed to navigate hard, calcified plaques. The statistical urgency of preventing amputation ensures that hospitals invest in these specialized technologies despite their higher cost. Furthermore, the aging population and diabetes epidemic increase the incidence of long-segment occlusions, which are technically challenging to treat. As per the Journal of Vascular Surgery, successful recanalization strategies can improve limb-related outcomes in patients with chronic total occlusions and critical limb-threatening ischemia. This clinical necessity creates a dedicated market niche with limited alternatives. Consequently, the Asia Pacific peripheral vascular devices market sees CTO devices as a high-growth area driven by the imperative to save limbs and improve quality of life for the most severely affected patients.

By Material Insights

The resistant materials segment had the major share of the regional market in 2025. The dominance of resistant materials segment in this regional market can be credited to their superior mechanical properties and biocompatibility required for long-term implantation and their ability to withstand the high mechanical stresses encountered in peripheral arteries, particularly in the femoropopliteal segment, which undergoes significant bending and compression during movement. According to research published in the Journal of Biomedical Materials Research, nitinol-based vascular implants provide high flexibility, fatigue resistance, and shape-memory properties that support their use in dynamic vascular environments. This mechanical reliability is critical for preventing stent fracture and restenosis, which are common complications in peripheral interventions. The statistical prevalence of long-lesion treatments requires materials that can provide consistent radial force over extended periods. As per the Society for Cardiovascular Angiography and Interventions, nitinol is widely used in peripheral vascular stents because its mechanical properties support flexibility and vessel conformability. These materials also offer excellent radiopacity, which aids in precise placement during fluoroscopy-guided procedures. Consequently, the Asia Pacific peripheral vascular devices market relies on resistant materials as the foundation of device design, ensuring structural integrity and long-term clinical success.

However, the semi-consistent sorts segment is projected to witness a prominent CAGR of 12.1% over the forecast period in this regional market owing to the demand for temporary scaffolding and reduced long-term foreign body presence and the development of bioresorbable vascular scaffolds, which provide temporary support to the vessel wall before dissolving completely. According to the Journal of the American College of Cardiology, bioresorbable scaffold technology has been investigated as a way to provide temporary vessel support while reducing the duration of permanent metallic implantation. This technological advancement appeals to patients and clinicians interested in reducing long-term foreign body exposure. The statistical reduction in late adverse events drives interest in these next-generation devices. As per clinical research published in major cardiovascular journals, bioresorbable vascular technologies continue to be evaluated for their effects on vessel remodeling, safety, and long-term clinical outcomes. Furthermore, these materials can be engineered to release anti-proliferative drugs in a controlled manner, enhancing therapeutic efficacy. Consequently, the Asia Pacific peripheral vascular devices market sees semi-consistent materials as a transformative opportunity to redefine the standard of care in peripheral interventions.

REGIONAL ANALYSIS

China Peripheral Vascular Devices Market Analysis

China is likely to maintain its leading position in the Asia Pacific peripheral vascular devices market over the next few years because of its large aging population, expanding healthcare infrastructure, and increasing burden of cardiovascular disease. According to the National Bureau of Statistics of China, the population aged 60 years and over reached 296.97 million in 2023, accounting for 21.1% of the national population. China accounts for approximately 35% of regional device consumption driven by a high prevalence of peripheral artery disease and government initiatives to expand coverage. This demographic weight supports a mature ecosystem of local and international device suppliers. Additionally, the basic medical insurance system provides broad population coverage for essential healthcare services, supporting baseline demand stability. As per the National Healthcare Security Administration, China had more than 1.3 billion people covered by basic medical insurance at the end of 2023, supporting broad access to healthcare services. Strong regulatory frameworks under the National Medical Products Administration also ensure product quality and safety. These factors collectively establish China as the undisputed leader shaping regional trends and supply chain dynamics.

Japan Peripheral Vascular Devices Market Analysis

Japan is likely to maintain a mature and technologically advanced position in the Asia Pacific peripheral vascular devices market over the next few years because of its aging population and established healthcare infrastructure. The country leads the region in the adoption of advanced technologies and minimally invasive techniques. According to Japan's Ministry of Health, Labour and Welfare, Japan operates a universal health insurance system that provides broad population coverage for medical services. This payer mix supports access to advanced vascular care and innovative treatment technologies. Additionally, Japan’s stable regulatory environment attracts multinational companies to launch new products first in the region. As per the Statistics Bureau of Japan, people aged 65 years and over represented approximately 29% of the population in 2024, reinforcing long-term demand for treatments associated with age-related vascular disease. High life expectancy also drives degenerative condition treatments. These attributes make Japan a benchmark for quality and innovation in the regional landscape.

India Peripheral Vascular Devices Market Analysis

India is likely to experience strong growth in the Asia Pacific peripheral vascular devices market over the next few years because of its large population, increasing healthcare access, and growing burden of diabetes and peripheral vascular disease. The country serves as a major hub for medical tourism and domestic vascular care. According to the International Diabetes Federation, approximately 90 million adults in India were living with diabetes in 2021, representing a substantial population at risk of vascular complications. This public sector scale drives volume for standard trauma and diabetic foot devices. Additionally, medical tourism attracts international patients seeking affordable care, boosting demand for premium implants. As per the International Diabetes Federation, India is among the countries with the largest populations of adults living with diabetes globally. Rising diabetes prevalence also fuels preventive care demand. These dynamics position India as a critical growth engine with unique cross-border market characteristics.

South Korea Peripheral Vascular Devices Market Analysis

South Korea is likely to maintain a sophisticated and technology-focused position in the Asia Pacific peripheral vascular devices market over the next few years because of its established national health insurance system and strong healthcare infrastructure. The country leads in the adoption of advanced technologies and minimally invasive techniques. According to the National Health Insurance Service, South Korea's national health insurance system covered eligible residents through employee-insured and self-employed-insured categories in 2024, while medical aid provided additional coverage for eligible groups. This payer mix supports access to advanced medical technologies and vascular procedures. Additionally, South Korea’s stable regulatory environment attracts multinational companies to launch new products first in the region. As per Statistics Korea, the population aged 65 years and over accounted for more than 19% of the population in 2024, highlighting the country's rapidly aging demographic profile. High life expectancy also drives degenerative condition treatments. These attributes make South Korea a benchmark for quality and innovation in the regional landscape.

Australia Peripheral Vascular Devices Market Analysis

Australia is likely to maintain a stable and premium position in the Asia Pacific peripheral vascular devices market over the next few years because of its developed healthcare system, high healthcare expenditure, and aging population. The country has a well-established healthcare system with strong coverage for vascular procedures. According to the Australian Institute of Health and Welfare, people aged 65 years and over represented approximately 17% of Australia's population in 2023, supporting continued demand for treatments associated with age-related vascular conditions. This demographic profile supports a robust market for both trauma and elective devices. Additionally, the high prevalence of sports injuries drives demand for advanced bracing and supportive devices. As per the Australian Bureau of Statistics, private health insurance participation remains substantial across the Australian population, supporting access to privately funded healthcare services. Strong regulatory standards also ensure product safety and quality. These factors ensure Australia remains a key market for high-value devices.

COMPETITIVE LANDSCAPE

The competition in the Asia Pacific Peripheral Vascular Devices Market is characterized by intense rivalry among established multinational corporations and specialized niche players who compete on technological superiority and clinical evidence. Large entities leverage their broad product portfolios and global distribution networks to dominate hospital accounts while smaller firms focus on innovative solutions for specific indications such as below the knee disease or venous disorders. The barrier to entry is high due to stringent regulatory requirements and the need for extensive clinical data to prove safety and efficacy. Competitive intensity is driven by the rapid pace of technological advancement including drug coating innovations and robotic assistance which forces continuous investment in research and development. Price competition exists but is secondary to product performance and long term patency rates which are critical for adoption. Reimbursement policies and health technology assessments further shape competitive dynamics by influencing market access and profitability. This environment requires participants to demonstrate clear clinical benefits and provide robust support services to maintain market share and drive growth in a sophisticated medical device sector

KEY MARKET PLAYERS

A few of the notable players leading the APAC Peripheral Vascular Devices market include

• Abbott Laboratories (U.S.)
• Cordis Corporation (U.S.)
• Medtronic (U.S.)
• Boston Scientific Corporation (U.S.)
• Covidien (U.S.)

Top Players in the Market

Medtronic plc

Medtronic plc maintains a robust presence in the Asia Pacific Peripheral Vascular Devices Market through its comprehensive portfolio of drug coated balloons stents and atherectomy systems. The company leverages advanced manufacturing technologies to produce high quality implants that support complex endovascular procedures across the region. Recently Medtronic expanded its clinical evidence base by launching large scale trials for next generation drug eluting technologies aimed at reducing restenosis rates in Asian populations. This commitment to innovation strengthens relationships with interventionalists who prioritize long term patient outcomes. By offering integrated solutions from diagnosis to treatment Medtronic ensures seamless procedural workflows. Their strategic focus on limb salvage programs enhances brand loyalty among vascular surgeons. These actions solidify their reputation as a leader in providing reliable and advanced peripheral vascular care products globally.

Boston Scientific Corporation

Boston Scientific Corporation plays a pivotal role in the Asia Pacific Peripheral Vascular Devices Market by combining extensive global reach with specialized expertise in minimally invasive therapies. The company offers a diverse range of devices including Ranger paclitaxel coated balloons and Viatrac peripheral stent systems designed for durability. Recently Boston Scientific introduced new lithotripsy technologies to treat heavily calcified lesions which are common in diabetic patients in the region. This material innovation addresses complex clinical challenges and improves procedural success rates. They also invest heavily in physician education programs to promote best practices in chronic total occlusion interventions. Through strategic partnerships with hospitals Boston Scientific improves access to advanced care. These efforts reinforce their competitive edge and drive adoption of their premium product lines in key Asian markets.

Abbott Laboratories

Abbott Laboratories contributes significantly to the Asia Pacific Peripheral Vascular Devices Market through its focus on innovative stent platforms and vascular closure solutions. The company specializes in drug eluting stents such as the Xience family which are widely used for peripheral artery disease. Recently Abbott launched enhanced delivery systems for its stents that improve navigability in tortuous anatomy common in Asian patients. This product expansion targets the growing demand for precise and safe device placement in complex cases. They also collaborate with research institutions to validate clinical performance in real world settings. By prioritizing surgeon feedback and clinical evidence Abbott builds strong brand trust. These actions enhance their market position by addressing specific needs of the vascular community and expanding their footprint in ambulatory surgical centers.

Top Strategies Used by Key Market Participants

Key players in the Asia Pacific Peripheral Vascular Devices Market primarily employ product innovation strategies by developing advanced drug coated technologies and specialized tools for chronic total occlusions to improve clinical outcomes. Companies invest heavily in research and development to create bioresorbable scaffolds and intravascular lithotripsy systems that address complex calcified lesions. Another major strategy involves expanding into emerging markets where healthcare infrastructure is improving and demand for peripheral interventions is rising due to aging populations. Manufacturers establish local distribution partnerships to navigate regulatory requirements and reduce costs effectively. Additionally participants focus on physician training and proctoring programs to build loyalty and ensure proper utilization of complex devices. Strategic acquisitions of smaller innovative firms allow large corporations to integrate new technologies quickly. These combined tactics enable companies to maintain leadership and capture growth in a competitive and evolving industry landscape.

MARKET SEGMENTATION

This research report on the Asia Pacific peripheral vascular devices market has been segmented and sub-segmented into the following categories.

By Product Type

• Stents
  • Balloon-Expandable Stent
  • Self-Expandable Stents
  • Secured Stents
• Embolic Protection Devices
• Angioplasty Balloons
  • Ordinary
  • Cutting
  • Scoring
  • Medication
• Aortic Stent-Grafts
• Inferior Vena Cava Filters
• Synthetic Surgical Grafts
• Peripheral Vascular Accessory Devices
• Vascular Closure Devices
• Chronic Total Occlusion (CTO) Devices
• PTA Balloon Catheters

By Material

• Resistant
• Semi-Consistent Sorts

By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC